Our study explored the cost-effectiveness and budget impact of neoadjuvant treatment by adding dual HER2-targeted agents to single HER2-targeted therapy with trastuzumab (T) in the neoadjuvant treatment of early HER2-positive breast cancer in Sri Lanka. The gene discussed is ERBB2; the disease is breast carcinoma.